anti-Programmed Cell Death 1 (PDCD1) Antibodies

Human Programmed Cell Death 1 (PDCD1) interaction partners

1. These results demonstrate the involvement of sPD (show HOXD13 Antibodies)-1 in the disease course of chronic HBV infection and indicate the potential to apply sPD (show HOXD13 Antibodies)-1 as a biomarker for differentiating IT from other phases and HCC (show FAM126A Antibodies) from other disease conditions in chronic HBV infection.

2. summarizes the latest research on PD-1 in infectious diseases and discusses its role in acute and chronic viral infection[review]

3. Our study demonstrates a cross-talk between PARPi and tumor-associated immunosuppression and provides evidence to support the combination of PARPi and PD-L1 (show CD274 Antibodies) or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer

4. Results show that high programmed cell death 1 (PDCD1, PD-1)methylation (mPDCD1) was associated with a significantly shorter overall survival after surgical resection.

5. Suggest that genetic polymorphisms of PD-1 function as sex-dependent risk factors for development of acute rejection in an Iranian kidney transplant population.

6. downregulation in PD-1 inhibitory signaling in RA could be attributed to increased serum sPD (show HOXD13 Antibodies)-1 and decreased synovial tissue PD-L1 (show CD274 Antibodies) levels

7. PD1 polymorphisms are associated with susceptibility to chronic hepatitis B infection in the Chinese population.

8. PD-1 seems to correlate with disease progression in epitheliotropic T cell dyscrasias ranging from minimal staining in prelymphomatous dyscrasias to significant staining in mycosis fungoides

9. in some tumor types, PD-L2 (show PDCD1LG2 Antibodies) expression is more closely linked to Th1 (show TH1L Antibodies)/IFNG (show IFNG Antibodies) expression and PD-1 and CD8 (show CD8A Antibodies) signaling than PD-L1 (show CD274 Antibodies)

10. Although mutational and immunologic differences have been proposed as the primary determinants of heterogeneous response/resistance to targeted therapies and immunotherapies, respectively, differential lesional gene expression profiles may also dictate anti-PD-1 outcomes

Mouse (Murine) Programmed Cell Death 1 (PDCD1) interaction partners

1. An examination of the mechanisms of immunity behind this long-term protection in PD-1 knockout mice showed a key role for parasite-specific CD8 (show CD8A Antibodies)(+) T cells even when CD4 (show CD4 Antibodies)(+) T cells and B cells responded to re-infection.

2. To test the in vivo activity of REGN2810, which does not cross-react with murine PD-1, knock-in mice were generated to express a hybrid protein containing the extracellular domain of human PD-1, and transmembrane and intracellular domains of mouse PD-1

3. The combination of tumor vaccination to induce high avidity tumor specific T cell responses and PD-1 blockade synergises to provide tumor therapy and 85% survival in the aggressive B16 melanoma model.

4. Blockade of PD-1 with monoclonal antibody may be an effective treatment during the postoperative period for restoring surgery-induced immunosuppression.

5. Data suggest that genetic or environmental factors that even moderately affect the expression of both PD-1 and FoxP3 (show FOXP3 Antibodies) can cause life-threatening autoimmune diseases by disrupting the T-cell homeostasis.

6. Data (including data from studies in transgenic/knockout mice) suggest that T-cell expression of Mirn155 is required to limit melanoma growth; miR (show MLXIP Antibodies)-155, Pdcd1, Pdcd1l1 (show CD274 Antibodies), and Ctla4 (show CTLA4 Antibodies) appear to regulate overlapping pathways promoting antitumor immunity. [Mirn155 = microRNA 155; Pdcd1 = programmed cell death 1 protein; Pdcd1l1 (show CD274 Antibodies) = programmed cell death 1 ligand 1 (show CD274 Antibodies) protein; Ctla4 (show CTLA4 Antibodies) = cytotoxic T-lymphocyte-associated protein 4 (show CTLA4 Antibodies)]

7. PD-1 plays a vital role in brain inflammation via regulation of Fgl-2 (show FGL2 Antibodies) after ICH (show ACE Antibodies), and that manipulation of PD-1 might be a promising therapeutical target in ICH (show ACE Antibodies).

8. We identified PD-1 to be specifically expressed in PLZF (show ZBTB16 Antibodies)(+) ILCp and revealed that the timing and order of expression of the transcription factors NFIL3 (show NFIL3 Antibodies), ID2, and TCF-1 (show HNF1A Antibodies) was critical. Importantly, induction of ILC (show CCL27 Antibodies) lineage commitment required only transient expression of NFIL3 (show NFIL3 Antibodies) prior to ID2 and TCF-1 (show HNF1A Antibodies) expression.

9. The identification of the role for PD-1 in regulating B cell-dependent antitumor immunity to Tn antigen highlights an opportunity to develop new therapeutic strategies targeting tumor-associated carbohydrate antigens

10. These findings suggest that PD-1 pathway blockade may reverse adaptive immune resistance following cyclic dinucleotide treatment, enhancing both local and systemic antitumor immunity.

Rhesus Monkey Programmed Cell Death 1 (PDCD1) interaction partners

1. Data show that CTLA-4 (show CTLA4 Antibodies)(+)PD-1(-) memory CD4 (show CD4 Antibodies)(+) T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut (show GUSB Antibodies), and contained replication-competent and infectious virus.

2. Compared to before immunosuppression, PD-1 expression increased at reactivation. Increased T cells before zoster is likely due to virus reactivation.

3. A PD-1(high) phenotype is associated with accelerated in vivo CD8 (show CD8A Antibodies) T cell turnover in SIV-infections, especially within the SIV-specific CD8 (show CD8A Antibodies) T cell pool.

4. High levels of PD-1 expression on CD4 (show CD4 Antibodies)(+) T cells in lymph nodes of rhesus macaques can serve as a valuable marker to identify T follicular helper cells.

5. Data indicate that PD-1 expression is increased as a result of T cell activation during a primary immune response as well as during persistent immune activation in macaques.

6. PD-1 can serve as a sensitive indicator of persistent, low-level virus replication